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ABSTRACT 
Julianne Jahui Huang: Short Palate Lung and Nasal Epithelium Clone 1  
and Airway Disease 
(Under the direction of Matthew R. Redinbo and Stephen L. Tilley) 
Airway disease such as asthma and infection is the cause substantial 
morbidity and mortality in the world today. Although modern medicine has developed 
many drugs for these conditions, these diseases remain highly prevalent and are 
often difficult to treat. 
Short palate, lung and nasal epithelium clone 1 (SPLUNC1) is an abundant 
multi-functional protein in the airway. It has been reported to have immune-
modulatory, surfactant and anti-microbial functions, and it regulates the airway 
surface liquid (ASL) height through the epithelial sodium channel (ENaC). This study 
focuses on utilizing SPLUNC1’s protective properties in combatting airway disease. 
Airway hyperresponsiveness (AHR) is a characteristic feature of asthma, yet 
its pathophysiology is still poorly understood. SPLUNC1 is dysregulated in allergic 
rhinitis and chronic rhinosinusitis with nasal polyps. However, SPLUNC1 regulation 
in asthmatics has not been investigated. Here, we show that in allergic asthmatic 
humans and house dust mite (HDM)-allergic mice, SPLUNC1 in the bronchoalveolar 
lavage (BAL) is reduced. We demonstrate that administration of SPLUNC1 to mice 
decreases their AHR and show that the molecular basis for this effect involves the 
coordination of the N-terminus with an electrostatic patch on the protein’s body. We 
propose that SPLUNC1 be further investigated for use in reducing AHR.  
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Pseudomonas aeruginosa, a primary lung pathogen in nosocomial 
pneumonia and in lung diseases such as cystic fibrosis and chronic obstructive 
pulmonary disease (COPD), causes considerable morbidity and mortality. SPLUNC1 
has been shown to neutralize and combat P. aeruginosa in vivo and in vitro. Here, 
we sought to establish a model for evaluating delivery of exogenous SPLUNC1 in 
acute lung infection and provide evidence that preemptive administration of 
SPLUNC1 may decrease bacterial burden.  
Lastly, we suggest that the administration of SPLUNC1 which we propose for 
asthma and lung infection results in SPLUNC1 mediated SPLUNC1 release in the 
lungs, effectively increasing the local protein concentration. This effect may utilize 
SPLUNC1’s natural protective properties to combat airway disease.  
We conclude that SPLUNC1 should be investigated further for use in asthma 
and bacterial pneumonia. 
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CHAPTER 1: INTRODUCTION 
Asthma 
Asthma, the most common chronic inflammatory lung disease in developed 
countries, affects approximately 26 million people annually in the United States 
alone and 300 million worldwide. Asthma has been estimated to cost 56 billion 
dollars in the United States and treating 20-30% of asthmatics constitutes 80% of 
the cost of managing all asthmatics (1, 2). The disease is influenced by both genetic 
and environmental components, such as pathogens and pollution, and has higher 
frequency and severity in boys compared to girls 0 to 14 years of age; interestingly, 
this prevalence reverses in adulthood with women having a higher incidence of 
asthma than men (3-5). The gender differences are attributed to sex hormones 
influencing β2 adrenoreceptors. Approximately 70% of asthmatics also have 
allergies and half of all asthmatics experience asthma attacks annually.   
Asthma is characterized by three cardinal features: airway inflammation, 
airflow obstruction, and airway hyperresponsiveness (AHR). Allergic inflammation 
involves many steps, affects patients from mild to severe asthmatics, and results in 
airway remodeling that can be correlated to the severity of symptoms (6). Airway 
edema, mucus hypersecretion, and smooth muscle remodeling all contribute to 
airflow obstruction and ultimately exacerbations (7, 8).  AHR or bronchial 
hyperreactivity is influenced by allergic inflammation causing airway remodeling but 
AHR is ultimately the result of smooth muscle contraction (9). These cardinal 
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features translate clinically into a number of symptoms including cough, wheezing, 
chest tightness, and shortness of breath. Untreated symptoms can progress into 
status asthmaticus (also termed near-fatal asthma), which results in respiratory 
failure and sometimes death. Approximately 4,000 people per year die from status 
asthmaticus in the United States.  
Fortunately, a number of highly effective therapies exist to treat the underlying 
inflammation in asthma. These drugs control asthma well when taken on a regular 
basis. Inhaled corticosteroids (ICS) are the mainstay of controller medicines for 
asthma. They work by a number of mechanisms, including the inhibition of 
proinflammatory cytokine synthesis. When ineffective alone, ICSs are combined with 
long-acting beta agonists (LABAs), long-acting anti-muscarinics, and leukotriene 
receptor antagonists. In addition to acting as long-term controller medicines, beta 
agonists are also used acutely to reverse bronchospasm by activating beta 
adrenergic receptors on airway smooth muscle (ASM), leading to rises in 
intracellular cAMP which promotes smooth muscle relaxation. This action translates 
clinically to bronchodilation and a reduction of airflow obstruction. 
The primary cell types mediating allergic asthma pathogenesis are dendritic 
cells, which are antigen presenting cells (APCs), B cells, mast cells, eosinophils, and 
T lymphocytes (T cells), specifically T helper 2 (Th2) cells that play a large role in 
allergic inflammation. Dendritic cells are the first cells activated in the pathway to 
allergic inflammation. They are residents on mucosal surfaces and are located near 
the basement membrane of the respiratory epithelium and function as cellular 
guards for pathogens and inhaled antigens (10). Dendritic cell numbers are amplified 
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in asthmatics and in an ovalbumin-sensitized allergic lung inflammation rat model 
(11, 12). They have been shown to play roles in AHR, increasing IgE concentration 
and in eosinophilia in the allergic airways. Dendritic cells are professional APCs and 
are key in adaptive immunity and also sensitization to antigens which results in 
allergic asthma via Th2 cells.  
Th2 CD4+ T helper cells are responsible for the release of many cytokines 
relevant to asthma. Although they secrete cytokines, including IL-2, IL-3, IL-4, IL-5, 
IL-7, IL-9, IL-13, IL-15, IL-16 and IL-17, they are most well-characterized for their 
secretion of IL-4, IL-5 and IL-13 in asthma. IL-4 has been reported to be responsible 
for skewing to a Th2 phenotype by promoting Th2 cell differentiation and inhibiting 
Th1 differentiation, eosinophil expansion, B-cell growth resulting in IgE production, 
and mucus production (5, 13, 14). IL-5 is well known for causing eosinophilia by 
promoting proliferation and survival of eosinophils in the airway. When IL-5 was 
reduced in eosinophilic asthma by anti-IL-5 antibodies, lung function was improved, 
exacerbations were reduced and the quality of life was improved (15). IL-13 effects 
have overlap with IL-4 in that they enhance IgE and mucus production, induce 
eosinophilic inflammation and also play a role in AHR and airway remodeling (16, 
17).    
The principal involvement of B cells in asthma is in the production of IgE 
antibodies, which is a key mediator of the allergic response and has been linked 
directly to disease severity (5). B cells are influenced by IL-4 to undergo 
immunoglobulin class switching resulting in the synthesis of IgE antibodies. 
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Circulating IgE, released by B cells, binds to mast cells via their high affinity FCεRI 
receptors. 
Mast cells are mucosal sentinels which, in normal tissues, have a role in 
angiogenesis, homeostasis, elimination of pathogens and play a role in innate and 
adaptive immunity (18). Although typically residing in the mucosa and connective 
tissues, they additionally congregate in smooth muscles and submucosal glands in 
asthmatic but not normal patients. Mast cells are activated in the asthmatic lung by a 
number of mechanisms. The best characterized mechanism is IgE-dependent 
activation. Mast cells have high affinity FCεRI receptors that bind IgE which, after 
encountering antigens, cross-link leading to mast cell activation (19). IgE-
independent activation also occurs in asthma when mast cells are stimulated by 
mediators such as ATP and adenosine, which activate purinergic receptors exposed 
on the cell surface. Mast cell activation results in degranulation, lipid mediator 
release, and cytokine synthesis. Mast cells, following activation by both IgE-
dependent and IgE-independent mechanisms, release a number of proinflammatory 
mediators including histamine, serotonin, prostaglandins and leukotrienes which 
cause smooth muscle contraction and airflow obstruction. Additionally, mast cells 
secrete the asthma-related cytokines IL-4, IL-5 and IL-13 which have previously 
been described as playing roles in eosinophilic airway inflammation and IgE 
synthesis. They also secrete profibrogenic cytokines leading to airway remodeling 
(20). 
Eosinophils are granulocytes that play a major role in the pathophysiology of 
allergic asthma. These leukocytes are monitored as an indication of disease severity 
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and inform management strategy (13).  The presence of eosinophils is associated 
with the Th2 cytokines IL-4, IL-5, which cause eosinophil expansion and survival and 
IL-13 expression. Eosinophil recruitment is due to eotaxin, RANTES and IL-5 and 
one of the main eosinophil products, major basic protein, damages the epithelium, 
increases AHR and causes mast cell degranulation. Eosinophils also cause goblet 
cell metaplasia, matrix deposition and smooth muscle hypertrophy (21). In addition 
to playing a critical role in the pathogenesis of Th2-high allergic asthma, eosinophils 
also mediate non-allergic eosinophilic asthma. In this asthma endotype, cytokines 
produced by the airway epithelium (thymic stromal lymphopoietin, IL-25, and IL-33) 
stimulate innate lymphoid cells to produce IL-5 and IL-13. In contrast to allergic 
eosinophilic asthma mediated by Th2 cells, IL-4 is not produced by the innate 
lymphoid cells, therefore IgE levels are low. Elucidation of these biological pathways 
involving mast cells and eosinophils has led to the development of new therapies 
including anti-IgE antibodies and anti-IL-5 antibodies, typically reserved for patients 
with severe asthma (22-24). 
Inflammation in the airway wall that develops through the mechanisms 
described above results in narrowing of the airway lumen. This airway narrowing, 
coupled with mucus hypersecretion into the lumen, leads to airflow obstruction. 
Clinically, this airflow obstruction manifests as wheezing and shortness of breath. In 
normal airways, mucus protects the epithelium by trapping inhaled particles and 
pathogens, but excess mucus secretion from the submucosal glands and goblet 
cells in asthmatics, particularly after allergen exposure, contributes substantially to 
airflow obstruction during asthma attacks.  
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While mechanisms that underlie the development of airway inflammation and 
airflow obstruction are well-characterized, the pathophysiology of AHR remains less 
well understood. AHR is defined as heightened contraction of ASM following 
exposure to stimuli that fail to or minimally stimulate contraction of ASM in normal 
subjects. Out of all the immune cells described above, only mast cells have been 
shown to play a critical role in AHR development. Mast cells infiltrate the ASM of 
asthmatics, and mediators released from mast cells are believed to contribute to 
AHR development. Whether or not ASM is intrinsically abnormal in asthma and in 
itself a major contributor to AHR development remains controversial. ASM 
hypertrophy and hyperplasia have been reported to contribute to AHR pathogenesis 
in asthma (25, 26). However, some investigations of airway smooth muscle (ASM) 
from asthmatic subjects suggest that it is intrinsically normal but becomes 
dysfunctional in the milieu of the asthmatic airway (27, 28).  
Over 30 years ago, a critical role for the epithelium in producing mediators 
that limit AHR was demonstrated when enhanced contraction was observed after the 
epithelia was denuded from the bronchi of dogs (29). This observation has been 
confirmed in multiple species, including mice and humans (30-64). Collectively, 
these studies strongly support the existence of an epithelial-derived smooth muscle 
relaxing factor (EDSMRF) that limits AHR. However, to date the identity of this 
EDSMRF has remained elusive. 
SPLUNC1 
Short palate, lung and nasal epithelium clone1 (SPLUNC1), also known as 
bactericidal/permeability-increasing fold containing family member A1 (BPIFA1), is 
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one of the most abundantly secreted proteins in mammalian airways, comprising up 
to 10% of total protein found in the airway surface liquid (ASL) (65). It was first 
discovered in mice in 1999 in a search for genes responsible for facial development 
and SPLUNC1 is primarily found in the airways and oral cavity; however, here we 
will mostly limit the discussion to airway involvement (66, 67). SPLUNC1 is encoded 
by genes on the long arm of chromosome 20 in the human genome and displays 
sequence and structural homology to the N-terminal portion of the antimicrobial 
bactericidal/permeability-increasing (BPI) protein (Figure 1.1) (68). It is a 256 amino 
acid long approximately 25 kDa protein which has a 19 amino acid signal sequence 
at its N-terminus that is cleaved off prior to the delivery of the mature protein to its 
final destination on mucosal surfaces. 
SPLUNC1 is a multi-functional protein that regulates ASL height, possesses 
immunomodulatory and antimicrobial properties, and demonstrates surfactant 
actions (69). SPLUNC1 controls airway hydration by its inhibition of the sodium 
epithelial channel (ENaC) (70). This regulation results in homeostatic fluid 
absorption in the airway and is believed to be important for maintaining normal ASL 
height, which is required for proper mucociliary clearance (MCC) essential for debris 
and pathogen removal in the lungs. SPLUNC1 accomplishes its regulation of ENaC 
through its N-terminal G22-A39 “S18” domain (71). Additionally, an electrostatic 
surface patch on the protein is responsible for presenting its N-terminal S18 region 
to ENaC in order to effect ASL height regulation (72). 
 SPLUNC1 has been reported to play an anti-inflammatory role in the context 
of allergic inflammation. Ovalbumin (OVA) has been used extensively to induce 
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allergic airway inflammation in mice (73, 74). SPLUNC1 levels are reduced in mouse 
lungs following OVA sensitization and knockout of the protein results in increased 
eosinophilic inflammation after OVA challenge (75). Additionally, Nogo-B, in the 
reticulon family of proteins, has been shown to regulate SPLUNC1 in the OVA model 
(76). Nogo-B-deficient mice demonstrate augmented eosinophilic lung inflammation 
in this model and SPLUNC1 was substantially reduced in the Nogo-B knockout 
mice. Interestingly, out of 40,000 genes examined in a genome-wide microarray 
comparing RNA expression from lungs of Nogo-deficient and wildtype mice, only 
SPLUNC1 was markedly reduced (278-fold or 95%). Restoration of SPLUNC1 by 
transgenic expression in the airway epithelium of Nogo-deficient mice rescued the 
phenotype, reverting inflammation back to wildtype levels. Collectively, these studies 
suggest that SPLUNC1 acts to limit the development of allergic airway inflammation, 
albeit by unknown mechanisms. Clinical data supporting these observations in 
mouse studies include studies showing that SPLUNC1 levels are low in the nasal 
lavage fluid and nasal tissues of patients with allergic rhinitis and chronic 
rhinosinusitis particularly within nasal polyps (77, 78) 
Due to SPLUNC1’s sequence similarity with the antimicrobial protein BPI, it 
was originally expected to have antimicrobial capabilities. Indeed, it has been shown 
to have activity against many bacteria including Pseudomonas aeruginosa, 
Burkholderia cenocepacia, Haemophilus influenzae and others (79-83). Part of its 
antimicrobial effects stem from its capacity to affect MCC through ASL height 
regulation via ENaC inhibition, as discussed above. It is also reported to have direct 
effects on Gram-negative bacteria through lipopolysaccharide (LPS)-binding and is 
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expected to disrupt biofilm formation potentially through its ability to function as a 
surfactant (84). 
SPLUNC1 has been reported to spread the ASL at the air-liquid interface. 
While the purpose of liquid-spreading surfactants in the alveoli has been extensively 
studied, the function of surfactants, such as SPLUNC1, in the conducing airways is 
less well characterized. There are reports that surfactants in the conducting airways 
aid MCC by increasing ciliary beating. Surfactants regulate immune cells and bind 
allergens, and a lack of surfactant is correlated with increased airway resistance in 
the lungs (85). Therefore, the ability of SPLUNC1 to function as a surfactant is yet 
another method in which the protein is able to protect the lungs. 
SPLUNC1 has been implicated in the pathogenesis of a number of disease 
states including cystic fibrosis (CF), lung cancer, allergy (described above) and 
chronic obstructive pulmonary disease (COPD). Both the cystic fibrosis 
transmembrane conductance regulator (CFTR) and SPLUNC1 serve to negatively 
regulate ENaC. In CF, mutations in CFTR results in the decreased presence of this 
critical chloride channel on epithelial cells. The decreased pH in the CF lung reduces 
SPLUNC1’s ability to inhibit ENaC (72). The combination of the inability CFTR and 
SPLUNC1 to inhibit CFTR in CF results in the dehydration of the ASL due to excess 
sodium transport and leads to a dysfunction in MCC. Despite the increased 
SPLUNC1 in the CF lung, there is an increased incidence of bacterial colonization, 
particularly with P. aeruginosa, B. cepacia and H. influenzae (86-89).  
Depending on the type of lung cancer, SPLUNC1 has been found to be 
upregulated and downregulated. In metastatic lung cancers, SPLUNC1 has been 
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detected outside its locations in the normal lung. It has been found in pleural 
effusions and lymph nodes and has been suspected of protectively reducing an 
oncogene correlated with nasopharyngeal carcinoma (69). Therefore, SPLUNC1 
regulation in terms of cancer depends on the particular disease. 
Finally, SPLUNC1 has been investigated in COPD and the results are varied. 
In one study, SPLUNC1 levels have been shown to be increased in sputum from 
patients with COPD (90). However, another study was not able to confirm this 
finding, showing instead no difference between patients with COPD and normal 
subjects (91). Therefore, more studies are necessary to determine whether or not 
SPLUNC1 may play a role in this common airway disease. 
Summary 
 Asthma is a common chronic inflammatory airway disease affecting 
approximately 8% of adults and 10% of children in the United States. It is influenced 
by genetic and environmental components and causes wheezing, shortness of 
breath, coughing and chest tightness in patients with the disease. Its defining 
characteristics include airway inflammation resulting in airway remodeling, reversible 
airflow obstruction, mucus hypersecretion and AHR. Although the pathobiology of 
airway inflammation and airflow obstruction is well characterized, AHR is less well 
defined. Studies in multiple species, including mouse and human, strongly suggest 
the existence of an EDSMRF; however, the identity of such a factor(s) has remained 
elusive. 
SPLUNC1 is a multifunctional protein in the airways with numerous protective 
abilities including ASL-height regulation (and therefore involvement in MCC), surface 
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tension reduction, antimicrobial function, and modulation of immune cell function. Its 
location in the airways facilitate these many protective abilities and its dysregulation 
has been indicated in several disease states including CF, lung cancer, and allergy. 
Although SPLUNC1 has been investigated in terms of allergic rhinitis and chronic 
rhinosinusitis, it has not been investigated in human allergic asthma. 
Here, we report SPLUNC1 levels in allergic asthmatics and house dust mite 
(HDM)-allergic mice, and present data suggesting a non-redundant role for 
SPLUNC1 in the pathogenesis of AHR. Finally, we propose that SPLUNC1 is the 
EDSMRF that has been sought for decades. 
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Figure 1.1 SPLUNC1 and BPI Structural Alignment 
Alignment of the full length SPLUNC1 (PBD: 4KGH) in green to the N-terminal 
domain of BPI (PDB: 1EWF) in blue. 
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CHAPTER 2: SPLUNC1 AND ASTHMA/ALLERGIC INFLAMMATION  
Introduction 
 SPLUNC1 is a multifunctional protective protein in the human airways that 
has been implicated in allergic airway inflammation such as in allergic rhinitis and 
chronic rhinosinusitis. It has also been investigated in mouse models of allergic 
inflammation. However, its involvement in human allergic asthma and one of the 
defining features of asthma, AHR, has not been investigated. Many studies involving 
mice and humans have pointed to the existence of an EDSMRF but have not 
conclusively found such a factor. In this study, we report SPLUNC1 levels in allergic 
asthmatics and HDM-allergic mice and suggest that SPLUNC1 is the elusive 
EDSMRF that has been long sought after in the literature. 
Materials and Methods 
Animals 
Female C57BL/6 mice were purchased from The Jackson Laboratory. 
SPLUNC1-/- mice were a kind gift from Dr. Y. Peter Di and Dr. Paul B. McCray Jr. at 
the University of Pittsburgh. SPLUNC1-/- mice were backcrossed 3 generations to 
the C57BL/6 background. SPLUNC1+/- N3 heterozygote breeders were used to 
generate SPLUNC1-/- mice and SPLUNC1+/+ littermate controls. All mice were 
housed in specific pathogen-free animal facilities with 12 h day and night cycles and 
provided food and water ad lib. 
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HDM-induced Allergic Airway Inflammation 
Allergic airway inflammation was induced in 7-13 week old female C57BL/6 
mice by intranasal (i.n.) administration of 25 µg of HDM (Greer Laboratories) for 12 
days. HDM was administered once a day for 5 consecutive days followed by 2 non-
treatment days, and this cycle repeated until 12 total doses of HDM were 
administered. Isoflurane was used for anesthesia for all i.n. instillations. 
BAL Fluid from Humans and Mice 
Bonchoalveolar lavage (BAL) fluid was collected from healthy and mild 
allergic asthmatic volunteers undergoing bronchoscopy at the U.S. Environmental 
Protection Agency in Chapel Hill, NC as previously described (92).  BAL was 
performed on HDM-allergic and PBS-control mice with 0.8 mL of Hank’s Balanced 
Salt Solution via tracheal cannula. 
Human Bronchial Epithelial Cell Culture 
Human Bronchial Epithelial Cells (HBECs) were obtained from freshly excised 
bronchial specimens from normal subjects as previously described (93). HBECs 
were cultured at air-liquid interface in a modified bronchial epithelial growth medium 
with 5% CO2 at 37°C and were used 4-6 weeks after seeding on 12 mm Millicell 
inserts (EMD Millipore). The apical surface of the HBECs was washed with PBS and 
a media change performed. An apical wash in 500 µL PBS was collected 1 h after 
media change, and SPLUNC1 concentration was determined by ELISA.  
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Measurement of AHR 
AHR was measured in tracheotomized, mechanically ventilated mice 
previously described (94). Briefly, mice were anesthetized with pentobarbital (70 
mg/kg), tracheotomy performed and an 18 gauge tracheostomy cannula inserted. 
Mice were then ventilated using a small animal ventilator (FlexiVent, Scireq) and 
paralyzed with atracurium. Airway mechanics were measured at baseline and 
following increasing doses of aerosolized methacholine (Mch) using a single 
sinusoidal frequency applied to the airway. Lung resistance was calculated using 
equation of motion-single compartment model. 
SPLUNC1 ELISA 
A sandwich ELISA was developed and used to detect SPLUNC1 protein in 
BAL supernatants. Primary monoclonal and secondary biotinylated polyclonal anti-
SPLUNC1 antibodies (R&D Systems) were used along with Avidin-HRP and TMB 
substrate (eBioscience).  
Western Blot 
SDS-PAGE was run on BAL supernatants and proteins transferred to a 
nitrocellulose membrane. Blots were incubated in primary anti-SPLUNC1 antibody 
and secondary HRP-conjugated antibodies (R&D Systems). Enhanced 
chemiluminescent substrate was used for detection. Densitometry analysis was 
performed using Image J software and normalized to a PonceauS 70 kDa band.  
Protein Preparation 
Wildtype and mutant proteins were expressed in BL21-CodonPlus cells and 
purified as previously described (72). BL21-CodonPlus competent cells were 
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transformed with the expression plasmid of interest and cultured in LB with ampicillin 
(100 μg/mL), chloramphenicol (34 μg/mL) and antifoam (50 μL) with shaking at 37°C 
until the OD600 reached 0.6. The cells were induced with 0.1 mM isopropyl-1-thio-D-
galactopyranoside (IPTG) and the temperature was reduced to 18°C for overnight 
growth. Cell pellets were lysed using sonication in the presence of lysozyme, DNase 
1, and protease inhibitor cocktail. Nickel and size exclusion chromatography were 
used for purification, and tobacco etch virus protease removed the histidine tag from 
the protein. 
Crystallization of SPLUNC1K138E 
Crystals of SPLUNC1K138E were grown in 6M ammonium nitrate, and 0.1M 
Tris (pH 8.5) and cryoprotected in 15% glycerol. Crystals diffracted to 2.7 Å with 
space group C2221. Molecular replacement with wildtype SPLUNC1Δ19 was used as 
a search model.   
Bone Marrow Mast Cell Culture  
Bone barrow cells were isolated from the femurs of 8-12 week old C57BL/6 
mice and grown in tissue culture for 6 weeks. Media was changed twice weekly and 
non-adherent cells were enriched for mast cells with IL-3. By 4 weeks, pure 
populations of mast cells were obtained.  
Bone Marrow Mast Cell IL-13 Assay 
Bone marrow mast cells (BMMCs) were treated with LPS from P. aeruginosa 
PA10 strain (0.2 µg/mL) followed by SPLUNC1 (0, 20, 100 and 200 µg/mL). IL-13 
secretion was measured in the media by ELISA (eBioscience) 24 h later.  
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Bone Marrow Mast Cell Hexosaminidase Release 
BMMCs were coated with a monoclonal IgE specific for human dinitrophenyl 
albumin (DNP, 100 ng/mL) and incubated overnight at 37°C. The next day, IgE-
loaded mast cells were stimulated with DNP antigen (5, 50 ng/mL) and incubated for 
20 m. Mast cell degranulation was assessed through detection of hexosaminidase in 
the media and comparing the hexosaminidase in the media to the total 
hexosaminidase present.  
Statistics 
All analyses were performed by Mann-Whitney test, Wilcoxon matched pairs-
signed rank test (GraphPad Prism) or MANOVA as indicated in figure legends. For 
MANOVA, total airway resistance data were log2 transformed and modeled as 
repeated measures in a multivariate model with genotype, treatment (where 
applicable), and Mch dose as fixed effect, and individual mouse as random effect 
factors. Between-subject effects fitted by the sum of the repeated measures were 
tested for significant differences between genotype, treatment, and Mch dose using 
F-statistics (JMP v.12.0.1, SAS). All data represent mean ± SEM. 
Study Approval 
The IACUC and IRB of the University of North Carolina at Chapel Hill 
approved all experiments. Written informed consent was obtained from each human 
subject. 
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Results 
SPLUNC1 is an Epithelial-derived Factor that is Reduced in Asthmatic Human 
and Allergic Mouse BAL 
 
 Mild allergic asthmatics (AAs) and normal volunteers (NVs) underwent 
bronchoscopy, and SPLUNC1 protein levels were measured in BAL fluid by ELISA. 
SPLUNC1 levels were markedly reduced or undetectable in samples from AAs 
(9.3+/-3.4 ng/mL). In contrast, most NVs had detectable SPLUNC1 at levels that 
were significantly higher than AAs (38.0+/-8.0 ng/mL) (Figure 2.1A).  To determine if 
mice with asthma-like airway disease would also develop a relative SPLUNC1-
deficiency in their airways, BAL fluid was collected following 12 days of mucosal 
sensitization with HDM. As shown in Figure 2.1B and similar to our findings in 
human BAL, SPLUNC1 levels in the airways of HDM-allergic mice were markedly 
lower than levels in PBS-treated controls (301.8+/-61.8 ng/mL vs. 885.2+/-113.8 
ng/mL).  Western blots confirmed the results obtained by ELISA, showing markedly 
reduced SPLUNC1 protein in the HDM-treated animals (Figure 2.1C).  
Next, to demonstrate that airway epithelia secrete SPLUNC1, we cultured HBECs at 
air-liquid interface and measured SPLUNC1 levels in the apical wash by ELISA. 
HBECs secrete abundant SPLUNC1 (Figure 2.2). Our findings of reduced SPLUNC1 
levels in HDM-allergic mice and asthmatic humans are consistent with in vitro 
studies on HBECs which showed that IL-13 suppresses SPLUNC1 mRNA 
expression, and in vivo studies in mice exposed to OVA (75, 95, 96).  Together, 
these results strongly support the conclusion that SPLUNC1 is an epithelial-derived 
factor that is reduced as a result of allergic airway inflammation.   
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SPLUNC1 Regulates AHR 
To investigate whether SPLUNC1-deficiency might contribute to AHR, airway 
mechanics during a graded Mch challenge were examined in naïve SPLUNC1-/- 
mice and their wildtype littermate controls. SPLUNC1-/- mice showed greater 
responsiveness to Mch, suggesting a link between SPLUNC1-deficiency and AHR 
(Figure 2.3). We next tested whether intratracheal (i.t.) instillation of SPLUNC1 to 
HDM-allergic mice would reduce AHR. Addition of SPLUNC1 1h prior to Mch 
challenge reduced AHR to levels similar to controls (Figure 2.4). These results 
indicate that SPLUNC1 plays a critical role in controlling AHR, and lead us to posit 
that restoration of SPLUNC1 may be therapeutic.  
K138E Mutant Structure and Function 
It has been reported that exercise in asthmatics leads to dehydrated or low 
ASL height, and that this effect on the airway produces AHR (9, 97). A well-
characterized function of SPLUNC1 is its capacity to regulate and restore low ASL 
height through its inhibition of ENaC (70, 71). We therefore hypothesized that 
SPLUNC1 reduces AHR through the regulation of ASL height and sought to 
elucidate the structural basis for this effect. In collaboration with the Tarran Lab, we 
have previously reported that wildtype SPLUNC1 (Δ19) regulates ASL height at 
normal but not acidic pH (72). Acidification of the airways occurs in asthma and in 
addition to the already reduced amount of SPLUNC1 in the asthmatic airways, we 
expect SPLUNC1’s ability to regulate ASL height to be diminished by the acidic 
environment (98). Data from the Tarran lab shows that a mutant, SPLUNC1K138E, 
regulates ASL height at acidic pH whereas the wildtype protein does not (Figure 
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2.5A). We were interested in determining the structure of this salient point mutant to 
obtain insight into a structure-function relationship. 
We solved the crystal structure of SPLUNC1K138E to 2.67 Å which revealed no 
major structural differences between the wildtype protein and the SPLUNC1K138E 
mutant (Figure 2.5B). This suggests that a structural change is not likely to cause 
the change in function. However, a limitation of this method is that the crystallization 
condition was basic (pH 8.5) rather than acidic. Since the functional differences 
between the wildtype and mutant protein exists in acidic rather than basic conditions, 
the next step would be to determine whether any structural differences exist at a 
more acidic condition. 
The Molecular Basis for SPLUNC1’s Effects on AHR 
SPLUNC1’s Effect on AHR is Independent of Effects on ASL Height 
We next wanted to establish the molecular basis for SPLUNC1’s reduction of 
AHR. As stated above, we hypothesized that SPLUNC1’s ability to regulate ASL 
height was responsible for its effects on AHR. To test this hypothesis, we utilized 
SPLUNC1 mutants and peptides with differential effects on ASL height (71). 
Surprisingly, the ENaC regulating N-terminal peptide of SPLUNC1, S18, failed to 
attenuate AHR (Figure 2.6A). In support of this result, the ENaC-inhibitor amiloride 
also failed to attenuate AHR at various concentrations (Figure 2.6B, 2.6C, 2.6D). We 
tested a variety of concentrations to maximize the ability of amiloride to inhibit ENaC 
despite reports of its half-life (99-101). Therefore, we conclude that inhibition of 
ENaC is not likely to be the cause of AHR-reduction. We additionally tested a few 
mutants, SPLUNC1D193N which regulates ASL height in both acidic and normal pH 
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(102), and SPLUNC1S190A and SPLUNC15XHis which both lack the ability to regulate 
ASL height (Figures 2.6C, 2.6D, 2.6E). All three mutants were able to reduce AHR, 
providing further evidence that SPLUNC1’s effect on AHR is independent of ENaC-
mediated changes in ASL-height.  
SPLUNC1’s N-terminus is Critical for AHR Reduction 
Since the ENaC-regulating S18 peptide did not reduce AHR, we hypothesized 
that the body of the protein, SPLUNC1Δ44, which is missing the 18 amino acids on 
the N-terminus (S18 segment), would inhibit AHR. Surprisingly, SPLUNC1Δ44, similar 
to S18, failed to attenuate AHR (Figure 2.7A). These data suggest that residues on 
both the N-terminus and the body of SPLUNC1 are essential for reducing AHR. To 
pinpoint the N-terminal residues critical for AHR reduction, we tested additional N-
terminal SPLUNC1 truncations. While SPLUNC1Δ34, ten amino acids longer than 
SPLUNC1Δ44, was ineffective at attenuating AHR (Figure 2.7B), SPLUNC1Δ30 and 
SPLUNC1Δ21 exhibited trends toward AHR attenuation (Figures 2.7C, 2.7D). We 
then hypothesized that the aspartic acid (D) residue, the only charged residue on the 
N-terminus, was critical for AHR-regulation. This residue may be involved in the N-
terminal presentation required for AHR reduction. Therefore, we removed the 
negative charge by changing the D to a nonpolar hydrophobic residue alanine (A). 
The SPLUNC1D29A mutant reduced AHR, indicating that the charged D alone was 
not responsible for the effect (Figure 2.7E). Overall, these data indicate that the N-
terminus and the body of SPLUNC1 are important for AHR reduction.  
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SPLUNC1’s Effect on AHR is Dependent on the Coordination of its N-terminus 
with an Electrostatic Patch on the Protein Body 
 
To further define the molecular basis of SPLUNC1’s capacity to modulate 
AHR, we examined surface electrostatics. We have previously shown that a surface 
“electrostatic patch” is involved in the proper presentation of the N-terminus (72). 
Thus, we hypothesized that the electrostatic patch may also be important for the 
observed effects on AHR as well. To test this hypothesis, we prepared a mutant in 
which the N-terminal region of the human protein was attached to the mouse protein 
body, which by sequence alignment does not contain the surface electrostatic patch. 
This exchange abrogated the ability of SPLUNC1 to reduce AHR (Figure 2.8A), 
indicating that the N-terminal domain and electrostatic patch work together to control 
AHR. We hypothesized that restoring the electrostatic patch on the mouse protein 
with the human N-terminus would restore the protein’s control of AHR. Thus, the 
mouse protein with the human N-terminus was modified to contain the human 
electrostatic patch. When we administered this protein prior to Mch challenge, the 
protein’s AHR-reducing ability was restored (Figure 2.8B). Conversely, when we put 
the mouse N-terminus on the human SPLUNC1 body, AHR was reduced (Figure 
2.8C) indicating that the mouse N-terminus is able to work with both the human 
protein body and the mouse protein body. We have not yet been able to test the full 
length wildtype mouse protein due to difficulties in purification, but the mouse protein 
body alone did not reduce AHR (Figure 2.8D). When we restored the non-charged 
mouse “electrostatic patch” region to the human protein body with the mouse N-
terminus, AHR was reduced. (Figure 2.8E). 
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Lastly, as reported previously, deletions of helix 4 and helix 6 from SPLUNC1 
do not alter its overall structure, and thus are expected to leave both the S18 and 
electrostatic regions intact (82). These two proteins reduced AHR in HDM-allergic 
mice to levels similar to that observed with wildtype SPLUNC1Δ19 (Figures 2.8F, 
2.8G).  Collectively, these data indicate that the N-terminal region of SPLUNC1 and 
the electrostatic patch work in concert to control AHR. 
SPLUNC1’s Mechanism of Action for AHR Reduction 
Mast cells are the most critical leukocyte in AHR development and we and 
others have shown that the absence of mast cells results in an inability to exhibit 
allergen-induced AHR (103, 104). Due to the co-localization of mast cells and 
SPLUNC1 in the mucosa, the capacity of mast cells to cause AHR, and the ability of 
SPLUNC1 to abolish AHR in allergic mice, we hypothesized that SPLUNC1 
functions to reduce AHR by inhibiting the activation of mast cells. To test this 
hypothesis, we isolated bone marrow cells from the femurs of C57BL/6 wildtype 
mice and grew them in culture, enriching for mast cells with IL-3.  To test whether 
SPLUNC1 could inhibit IL-13 production by mast cells, a Th2 cytokine important for 
AHR, BMMCs were treated with LPS to induce IL-13 secretion. Cells were then 
administered SPLUNC1 and secreted IL-13 was measured in the media 24 h later. 
We observed a SPLUNC1 dose-dependent trend toward reduced IL-13 secretion 
(Figure 2.9).  
Next, we tested the potential of SPLUNC1 to inhibit antigen-mediated mast 
cell degranulation. Mast cells were coated with IgE overnight specific for human 
DNP. The next day, IgE-loaded mast cells were treated with SPLUNC1 and then 
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stimulated with DNP antigen and incubated for 20 m. Mast cell activation was 
assessed by measuring hexosaminidase in the media as a percentage of the total 
hexosaminidase present (105). SPLUNC1 did not alter the antigen-mediated mast 
cell degranulation (Figure 2.10). 
These studies suggest that the presence of SPLUNC1 may reduce the 
secretion of IL-13 from mast cells. If the trends we observed are confirmed with 
more mast cell cultures, then it is possible that inhibition of mast cell IL-13 synthesis 
may in part be responsible for SPLUNC1’s ability to attenuate AHR. 
Discussion 
Using samples from allergic asthmatics, we have shown that levels of the 
normally abundant airway protein SPLUNC1 are significantly reduced. Similarly, the 
induction of allergic airway inflammation in mice results in reduced SPLUNC1 levels. 
SPLUNC1-deficient mice are hyper-responsive to Mch, and restoring SPLUNC1 to 
the airway of HDM-allergic mice reverses the AHR that develops in this model. 
Collectively, these data suggest that SPLUNC1 is an epithelial-derived relaxing 
factor, something that has been sought for 30 years.  Further, they suggest that 
SPLUNC1 deficiency may contribute to AHR development in asthma.  
SPLUNC1 is a multi-functional protein in the airway with antimicrobial, 
surfactant, ASL-height regulating, and immunomodulatory activities. Mice lacking 
SPLUNC1 show enhanced eosinophilic airway inflammation and goblet cell 
hyperplasia following OVA sensitization (75). And allergic inflammation significantly 
reduces SPLUNC1 levels in the lungs (76). These studies on inflammation, 
collectively with our data showing low SPLUNC1 levels in asthmatics and its 
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importance in AHR, suggest that correction of SPLUNC1-deficiency in asthmatics 
may be therapeutic. 
One of SPLUNC1’s well-characterized functions is its ability to regulate 
ASL height through ENaC (70, 71). Here we report that the ENaC-regulating 
SPLUNC1 peptide S18 is unable to reduce AHR, giving an indication that ENaC-
regulated changes in ASL height is not likely to be the route of AHR reduction. In 
support of this finding, the ENaC inhibitor amiloride also failed to reduce AHR. It is 
known that asthma exacerbations are correlated with acidification of the airways 
(98). Our group has previously shown that the S18 peptide, and point mutant 
SPLUNC1D193N are able to regulate ASL height at both normal and acidic pH (72). 
Despite the fact that both are able to regulate ASL height independent of pH, 
SPLUNC1D193N reduced AHR while S18 did not. We additionally tested two mutants 
which do not regulate ASL height (SPLUNC1S190A, SPLUNC15XHis) and showed that 
these proteins significantly reduced AHR. Therefore, we conclude that SPLUNC1’s 
ability to alter ASL height via ENaC inhibition is not the mechanism for its ability to 
affect AHR. 
Since SPLUNC1Δ44, which lacks the first 18 amino acids of the protein, did not 
reduce AHR, we felt confident that the N-terminus of the protein was critical for the 
observed effects on AHR. Interestingly, the first two N-terminal residues of 
SPLUNC1 exhibit structural similarity to the muscarinic receptor antagonist, 
scopolamine. Both scopolamine and SPLUNC1’s N-terminal residues glutamine and 
phenylalanine contain an amine group and an aromatic ring. We thus hypothesized 
that SPLUNC1 might act as a muscarinic receptor antagonist, preventing Mch from 
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inducing AHR when given before Mch challenge. However, when we removed the 
two N-terminal residues from the protein, its ability to abolish AHR was not 
eliminated.  These data suggest that muscarinic receptor antagonism is not 
responsible for the effects of SPLUNC1 on AHR. 
We previously reported that an “electrostatic patch” on SPLUNC1 is involved 
in presenting the protein’s N-terminus (72). We hypothesized that the electrostatic 
patch may be involved in N-terminus presentation for AHR-reduction as well. Indeed, 
we were able to support this hypothesis by preparing a few mutant proteins. The first 
was a mouse-human chimeric protein that naturally does not have an electrostatic 
patch. This protein, containing the mouse body and human N-terminus was not able 
to reduce AHR. However, when the hybrid protein was conferred the human 
electrostatic patch by replacing amino acid sequences in the protein body, the ability 
to affect AHR was restored, indicating the requirement of the N-terminal coordination 
with the electrostatic patch for AHR-reduction. We also prepared the complementary 
human protein with a mouse N-terminus and the human protein with the mouse 
terminus which was given the mouse “electrostatic patch” region. Both of these 
proteins reduced AHR, indicating the mouse N-terminus may be able to coordinate 
with both the mouse protein body and the human protein body. To further support 
the hypothesis that the N-terminus and the protein body are both needed for AHR-
regulation, we focused on two major alpha helices, helix 4 and 6, which flank the 
beta-stranded region of the SPLUNC1 protein. We deleted each alpha helix from the 
protein individually, which are expected to leave the electrostatic patch and S18 
region intact. Both proteins significantly reduced AHR in the HDM-allergic mice. 
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Thus, these data provide further evidence that both the N-terminus and electrostatic 
patch are necessary for SPLUNC1 to effect AHR. 
Defining the portions of the SPLUNC1 protein that mediate its effect on AHR 
reduction is critical for the development of SPLUNC1-derived proteins as 
therapeutics for asthma. Equally important is understanding the cellular and 
molecular mechanisms by which SPLUNC1 influences AHR. To begin to define this 
mechanism, we chose to examine SPLUNC1’s effect on mast cell activation. Mast 
cells are critical effector cells in AHR development, in part through their synthesis of 
IL-13 (106, 107). Our data suggests that SPLUNC1 may inhibit IL-13 synthesis by 
mast cells. Since we only observed a trend toward IL-13 reduction, more 
experiments with additional BMMC cultures are warranted. Human mast cells can 
also be cultured in vitro, and similar experiments with human mast cells could further 
support this mechanism of action in IL-13 inhibition is seen in human cells. IL-13 has 
long been recognized as a key mediator in AHR development. It is tempting to 
speculate that the down-regulation of SPLUNC1 in the allergic airway results in 
increased IL-13 synthesis by mast cells, resulting in AHR development. 
In summary, we have demonstrated that one of the most abundant proteins in 
the normal airway, SPLUNC1, is reduced in allergic asthmatics and in mice 
sensitized with the common aeroallergen HDM. Furthermore, we show that reduced 
airway SPLUNC1 enhances bronchoconstriction in response to Mch. Importantly, 
this AHR can be reversed by restoring SPLUNC1, and the molecular basis for this 
effect on airway physiology involves electrostatic coupling of the SPLUNC1 body 
with portions of the N-terminus. These results suggest that strategies to increase 
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endogenous SPLUNC1 levels or the administration of recombinant SPLUNC1 to the 
airway be further investigated as novel approaches for treating asthma.  
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Figure 2.1. SPLUNC1 is Reduced in Allergic Airways 
A. Human BAL was obtained from normal volunteers (Control) and allergic 
asthmatics (Asthmatic) undergoing bronchoscopy and SPLUNC1 levels were 
measured in BAL supernatants by ELISA. n=20 for Control group and n=21 for 
Asthmatic group.  
B. C57BL/6 mice were treated with HDM (25 μg i.n.) or PBS (Control) for 12d, then 
SPLUNC1 levels were measured in BAL supernatants by ELISA. n=17 for both 
groups. 
C. BAL supernatants from HDM-sensitized and Naïve (Control) mice were evaluated 
via Western blot densitometry analysis. n=6 for both groups. Mann-Whitney test. 
**P<0.005 ***P<0.0005 
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Figure 2.2 HBECs Secrete SPLUNC1 
HBECs were cultured at air-liquid interface for 4-6 weeks and SPLUNC1 levels were 
measured in apical wash samples 1h after the addition of apical PBS (20 µL) by 
ELISA. n=4. Mann-Whitney test. *P<0.05 
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Figure 2.3 SPLUNC1-/- Mice are Hyperresponsive to Methacholine 
Airway resistance was measured in SPLUNC1-/- (blue triangles) and SPLUNC1+/+ 
(black squares) mice following a graded Mch challenge. n=25-27 **P<0.005 by 
MANOVA. 
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Figure 2.4 Administration of Wildtype SPLUNC1Δ19 Abolishes Allergen-induced 
AHR 
C57BL/6 mice were treated with HDM (25 μg i.n.) or PBS for 12d. One day after the 
last HDM challenge, mice were dosed with wildtype SPLUNC1Δ19 (150 μg i.t.) or 
PBS and AHR to methacholine was measured 1h later. Open circles: PBS+PBS 
group; black squares: HDM+PBS group; blue triangles: HDM+SPLUNC1Δ19. n=14-
15 for all groups. *P<0.05 in B by MANOVA. 
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Figure 2.5 SPLUNC1K138E Protein Restoration of ASL-height at Acidic pH is Not 
the Result of a Structural Change 
A. Mean ASL height in HBEC cultures at pH 6.0 8 h after addition of wildtype (WT) 
SPLUNC1, S18 peptide or SPLUNC1K138E (n ≥ 7 for each group). Mann-Whitney 
test. ***P<0.0005 
B. Crystal structure of SPLUNC1K138E mutant (pink) at 2.7 Å resolution 
superimposed on wildtype protein (purple), with a close-up of the normal K138 and 
mutant E138  
C.  Electron density of the glutamic acid at position 138 in the mutant structure; 2Fo-
Fc map contoured at 2σ 
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Figure 2.6. SPLUNC1’s Effect on AHR is Independent of Effects on ASL Height 
C57BL/6 mice were treated with HDM (25 μg i.n.) for 12d. One day after the last 
HDM challenge, mice were dosed with  
A. S18 (6 mmol i.t.)   
B. Amiloride (0.1 µmol i.t.) 
C. Amiloride (0.5 µmol i.t.) 
D. Amiloride (3.75 µmol i.t.) 
E. SPLUNC1D193N (150 μg i.t.)  
F. SPLUNC1S190A (150 μg i.t.)  
G. SPLUNC15XHis (150 μg i.t) 
or PBS and AHR to methacholine was measured 1h later. Black squares: HDM+PBS 
group; blue triangles: HDM+treatment group. n=10-15 for all groups.  P>0.05 in A, B, 
C and D * P<0.05 in G, ***P<0.0005 in E and F by MANOVA. 
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Figure 2.7 SPLUNC1’s N-terminus is Critical for AHR Reduction  
C57BL/6 mice were treated with HDM (25 μg i.n.) for 12d. One day after the last 
HDM challenge, mice were dosed with  
A. SPLUNC1Δ44 (150 μg i.t.)  
B. SPLUNC1Δ34 (150 μg i.t.)  
C. SPLUNC1Δ30 (150 μg i.t.)  
D. SPLUNC1Δ21 (150 μg i.t.)  
E. SPLUNC1D29A (150 μg i.t.)  
or PBS and AHR to methacholine was measured 1h later. Black squares: HDM+PBS 
group; blue triangles: HDM+treatment group. n=9-17 for all groups.  P=0.47 in A, 
P=0.50 in B, P=0.08 in C, P=0.06 in D, ***P<0.0005 in E by MANOVA. 
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Figure 2.8 Both the N-terminus and Electrostatic Patch are Necessary for AHR-
reduction 
C57BL/6 mice were treated with HDM (25 μg i.n.) for 12d. One day after the last 
HDM challenge, mice were dosed with  
A. SPLUNC1mSP1hNT (150 μg i.t.)  
B. SPLUNC1mSP1hNT+EP (150 μg i.t.)  
C. SPLUNC1hSP1mNT (150 μg i.t.)  
D. SPLUNC1mSP1Δ45 (150 μg i.t.)  
E. SPLUNC1hSP1mNT+EP (150 μg i.t.)  
F. SPLUNC1Δα4 (150 μg i.t.)  
G. SPLUNC1Δα4 (150 μg i.t.)  
or PBS and AHR to methacholine was measured 1h later. Black squares: HDM+PBS 
group; blue triangles: HDM+treatment group. n=8-15 for all groups. P>0.05 in A, 
*P<0.05 in B, C, and G, **P<0.005 in D and F by MANOVA. 
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Figure 2.9 SPLUNC1 Exhibits Dose-dependent Reduction of IL-13 Secretion in 
Mast Cells 
Mast cells were treated with PAO1 LPS (0.2 µg/mL) followed by SPLUNC1 (0, 20, 
100, and 200 µg/mL) and IL-13 secretion measured in the media 24 h later. Data 
analyzed by Wilcoxon matched-pairs signed rank test. 
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Figure 2.10 SPLUNC1 Does Not Reduce Allergen-induced Mast Cell 
Degranulation 
Mast cells coated in anti-dinitrophenyl albumin (DNP) IgE were treated with 
SPLUNC1 at 0, 1, 4, 16, 250, 1000 and 2250 µg/mL and stimulated with DNP 
antigen (5, 50 ng/mL). Percent hexosaminidase degranulation was measured as the 
hexosaminidase in the media compared to total hexosaminidase present.  
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CHAPTER 3: SPLUNC1 AND LUNG INFECTION 
Introduction 
Pneumonia kills approximately 35% of patients with healthcare-associated 
infections in the US, and the common opportunistic pathogen Pseudomonas 
aeruginosa is the primary Gram-negative infectious bacterium cultured from the 
lungs of patients with hospital-acquired pneumonia (108, 109). Additionally, P. 
aeruginosa colonizes the airway of 80-85% of patients with cystic fibrosis by age 20, 
and infects patients with moderate, severe, and exacerbated COPD (110-112). 
Although antibiotics such as antipseudomonal beta-lactams, aminoglycosides and 
quinolones are available, the prevalence of antimicrobial resistance is extensive and 
growing (113-116). Thus, new methods to help eradicate P. aeruginosa infections 
are urgently needed. 
 SPLUNC1 has been shown to neutralize and combat P. aeruginosa both in 
vitro and in vivo (79, 80, 117-119). The published in vivo studies include studies 
performed on knockout and transgenic SPLUNC1 mice. These data suggest that 
delivering SPLUNC1 to the lungs of infected subjects may be therapeutic. To test 
this hypothesis, we evaluated the efficacy of recombinant human SPLUNC1 to 
inhibit bacterial growth in vivo using a murine model of P. aeruginosa pneumonia.  
We present data showing that SPLUNC1 may decrease bacterial burden in an acute 
lung infection model with P. aeruginosa. 
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Materials and Methods 
Animals 
Female C57BL/6 mice bred in-house or purchased from The Jackson 
Laboratory were used for these studies. Mice were housed in specific pathogen-free 
animal facilities with 12 h day and night cycles and provided food and water ad lib. 
Protein Preparation 
Protein was expressed in BL21-CodonPlus cells and purified as previously 
described (72). BL21-CodonPlus competent cells were transformed with the 
expression plasmid of interest and cultured in LB with ampicillin (100 μg/mL), 
chloramphenicol (34 μg/mL) and antifoam (50 μL) with shaking at 37°C until the 
OD600 reached 0.6. The cells were induced with 0.1 mM IPTG and the temperature 
was reduced to 18°C for overnight growth. Cell pellets were lysed using sonication in 
the presence of lysozyme, DNase 1, and protease inhibitor cocktail. Nickel and size 
exclusion chromatography were used for purification, and tobacco etch virus 
protease removed the histidine tag from the protein. 
Bacterial and SPLUNC1 Dosing 
P. aeruginosa PAO1 strain obtained from the Matthew Wolfgang laboratory 
on the UNC campus was grown overnight in LB broth at 37°C in a sterile round 
bottom tube that allows for venting. A 0.5 mL aliquot of the overnight culture was 
diluted into 24.5 mL sterile LB and grown at 37°C in an incubated shaker until log 
phase growth (OD600 0.6-1.2). The mice were given 0.3 mg SPLUNC1 or PBS i.t. 
followed by 5 x 106 colony forming units (CFU) of PAO1 in PBS + 1% protease 
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peptone 1 h later. Mice were kept on heating pads overnight and left lungs were 
harvested 1 d later.  
Lung Harvest 
Isoflurane euthanasia was performed and the left lung removed from each 
mouse. The lung was weighed, minced, and stored in PBS with 7% fetal bovine 
serum and 2% Triton X-100. Lungs were homogenized with metal beads in a Next 
Advance Bullet Blender. Lung homogenates were plated on LB agar plates overnight 
and colonies counted 1 d later. 
Statistics 
Analyses were performed by Mann-Whitney test. All data represent mean ± 
SEM. 
Study Approval 
The IACUC of the University of North Carolina at Chapel Hill approved all 
experiments.  
Results 
In order to establish an acute lung infection, we tested a 5 x 106 CFU P. 
aeruginosa PAO1 strain dose on C57BL/6 mice bred in-house or purchased from 
The Jackson Laboratory. Lungs were harvested one day later and CFU/mg of lung 
determined. We successfully established infection and discovered that The Jackson 
Laboratory animals had higher CFU/mg lung than in-house bred animals (Figure 
3.1).  
In order to observe a more dramatic reduction of infection with SPLUNC1 
administration, we chose to proceed with The Jackson Laboratory animals which 
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had a higher CFU/mg lung count. We administered SPLUNC1 1 h prior to infection 
with PAO1 and discovered a trend toward reduction of CFU/mg of lung with 
SPLUNC1 administration (Figure 3.2). In summary, we show that we were able to 
establish a model for the delivery of exogenous SPLUNC1 to an acute lung infection 
and provide evidence that SPLUNC1 may reduce bacterial load in this model. 
Discussion 
SPLUNC1 has previously been shown to possess antimicrobial properties, 
which includes activity against the Gram-negative bacterium, P. aeruginosa (79, 80, 
117-119). The published studies examined SPLUNC1’s activity against P. 
aeruginosa either in vitro, or in vivo in knockout and transgenic mice. No study to 
date has reported administering exogenous SPLUNC1 to mice. In order to determine 
whether SPLUNC1 has the potential to be used therapeutically against P. 
aeruginosa infection, and to determine the molecular basis for SPLUNC1’s ability to 
combat infection in vivo, we needed to be able to deliver exogenous SPLUNC1 in 
acute lung infection. In a model of P. aeruginosa pneumonia, we show that the 
delivery of SPLUNC1 trends towards reduction of bacterial burden in mice. 
Interestingly, we observed a trend toward increased bacterial burden in purchased 
mice compared to mice bred in our animal facility when given P. aeruginosa alone. 
One potential explanation for this observation is stress induced by travel and 
acclimation to a new housing environment. Stress is known to be 
immunosuppressive through a number of mechanisms. One mechanism is 
catecholamine-induced elevation of cAMP in immune cells via beta-adrenergic 
stimulation. Rises in intracellular cAMP inhibits immune cell migration and activation. 
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Using purchased mice, we were able to show a trend towards lower CFUs in 
mice treated with rSPLUNC1 (Figure 3.2). However, the variability in the severity of 
infection was high, thus contributing to the lack of statistical significance. More 
experiments with larger numbers of mice will be necessary to determine whether this 
trend that we observed is a real effect of SPLUNC1, and if so, would suggest that 
administration of rSPLUNC1 be evaluated further for use in treating lung infections 
such as P. aeruginosa. 
Future Directions 
In this study, we begin to evaluate the ability of exogenous SPLUNC1 
administration to reduce bacterial burden in vivo. One challenge mentioned above 
was that the error was higher than desired in the infection group which affected our 
ability to detect statistical significance from the results obtained. Therefore, future 
directions include more practice with infectious dosing to normalize the dose 
delivered for a more consistent result. Once more consistent infections are 
established, rSPLUNC1 would be tested again and statistical significance evaluated. 
Our group has published in vitro studies which detail the structural elements 
critical for SPLUNC1’s antimicrobial properties (82). If anti-infective actions of 
rSPLUNC1 are established in vivo, then future directions include testing mutants 
with reduced surfactant functions as well as bacteriostatic and LPS-binding activity 
against P. aeruginosa in vivo. As we also have mutants with reduced activity against 
Burkholderia cenocepacia, once we obtain consistency with P. aeruginosa infection, 
we intend to establish an infectious model with B. cenocepacia. Wildtype and mutant 
proteins may then be tested for their ability to reduce B. cenocepacia infection. 
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Lastly, we have prepared a mutant protein which has gained function against the 
Gram-positive Staphylococcus aureus. Future directions include testing this mutant 
protein against S. aureus in mice.  
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Figure 3.1. The Jackson Laboratory vs. In-house Mouse PAO1 Infection 
The Jackson Laboratory and In-house bred C57BL/6 mice were treated with PAO1 
(5 x 106 CFU i.t.). One day later, the left lung from each mouse was harvested, 
homogenized and plated for colony counts. n = 5 for both groups.  
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Figure 3.2 SPLUNC1 Reduces CFU Load in PAO1 Lung Infection  
In-house bred C57BL/6 mice were treated with SPLUNC1 (0.3 mg i.t.) one hour 
before PAO1 infection (5 x 106 CFU i.t.). One day later, the left lung from each 
mouse was harvested, homogenized and plated for colony counts. n=2 for (-) 
Control, n=7 for PBS+PAO1 and n=5 for SPLUNC1+PAO1 groups.  
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CHAPTER 4: ADMINISTRATION OF SPLUNC1 RESULTS IN SECRETION OF 
SPLUNC1 
 
Introduction 
Studies from our group and others address SPLUNC1’s protective properties 
in the context of allergic inflammation and infection (75, 76, 79-83, 96, 118-122). 
Chapters 2 and 3 suggest that administration of SPLUNC1 or methods to increase 
the endogenous SPLUNC1 be investigated for treatment of asthma and lung 
infection. Overall, we have shown that the local increase in SPLUNC1 concentration 
in the lung acts protectively in these diseases. While the literature has shown that 
delivery of drugs such as α1-antitrypsin, beta-2-agonists and glucocorticoids results 
in an increase in SPLUNC1 concentration, we advocate that exogenous SPLUNC1 
delivery should also be considered (78, 95, 119, 123). Here, we show that the 
delivery of exogenous SPLUNC1 results in feedback releasing endogenous 
SPLUNC1. We explore the possibility of utilizing this effect to assist in combatting 
AHR and lung infection as described in chapters 2 and 3. 
Materials and Methods 
Animals 
Female C57BL/6 mice were purchased from The Jackson Laboratory. 
SPLUNC1-/- mice were a kind gift from Dr. Y. Peter Di and Dr. Paul B. McCray Jr. at 
the University of Pittsburgh. SPLUNC1-/- mice were backcrossed 3 generations to 
the C57BL/6 background. SPLUNC1+/- N3 heterozygote breeders were used to 
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generate SPLUNC1-/- mice and SPLUNC1+/+ littermate controls. All mice were 
housed in specific pathogen-free animal facilities with 12 h day and night cycles and 
provided food and water ad lib. 
HDM-induced Allergic Airway Inflammation 
Allergic airway inflammation was induced in 7-13 week old female C57BL/6 
mice by i.n. administration of 25 µg of HDM (Greer Laboratories) for 12 days. HDM 
was administered once a day for 5 consecutive days followed by 2 non-treatment 
days, and this cycle repeated until 12 total doses of HDM were administered. 
Isoflurane was used for anesthesia for all i.n. instillations. 
SPLUNC1 Dosing and BAL Collection 
SPLUNC1 was administered to mice (150 µg i.t.) and BAL performed with 0.8 
mL of Hank’s Balanced Salt Solution via tracheal cannula 1, 12, 24, 48 and 72 h 
after administration. 
Cell Culture 
HBECs were obtained from freshly excised bronchial specimens from normal 
subjects as previously described (93). HBECs were cultured at air-liquid interface in 
a modified bronchial epithelial growth medium with 5% CO2 at 37°C and were used 
4-6 weeks after seeding on 12 mm Millicell inserts (EMD Millipore). The apical 
surface of the HBECs was washed with PBS and a media change performed. 
SPLUNC1 (50 µg) was administered to the apical surface of the cells at media 
change and an apical wash in 500 µL PBS was collected 0.5, 1, 1.5, 2, 2.5 and 3 h 
after media change. SPLUNC1 concentration was determined by ELISA.  
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SPLUNC1 ELISA 
A sandwich ELISA was used to detect SPLUNC1 protein in BAL supernatants 
and HBEC samples. Primary monoclonal and secondary biotinylated polyclonal anti-
SPLUNC1 antibodies (R&D Systems) were used along with Avidin-HRP and TMB 
substrate (eBioscience).  
Western Blot 
SDS-PAGE was run on BAL supernatants and proteins transferred to a 
nitrocellulose membrane. Blots were incubated in primary anti-SPLUNC1 antibody 
and secondary HRP-conjugated antibodies (R&D Systems). Enhanced 
chemiluminescent substrate was used for detection.  
Protein Preparation 
Proteins were expressed in BL21-CodonPlus cells and purified as previously 
described (72). BL21-CodonPlus competent cells were transformed with the 
expression plasmid of interest and cultured in LB with ampicillin (100 μg/mL), 
chloramphenicol (34 μg/mL) and antifoam (50 μL) with shaking at 37°C until the 
OD600 reached 0.6. The cells were induced with 0.1 mM IPTG and the temperature 
was reduced to 18°C for overnight growth. Cell pellets were lysed using sonication in 
the presence of lysozyme, DNase 1, and protease inhibitor cocktail. Nickel and size 
exclusion chromatography were used for purification, and tobacco etch virus 
protease removed the histidine tag from the protein. 
Statistics 
All analyses were performed by Mann-Whitney and Wilcoxon matched-pairs 
signed rank tests as indicated (GraphPad Prism). All data represent mean ± SEM. 
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Study Approval 
The IACUC of the University of North Carolina at Chapel Hill approved all 
experiments.  
Results 
Administration of SPLUNC1 Results in Secretion of SPLUNC1 
HBECs cultured at air-liquid interface were exposed to wildtype SPLUNC1Δ19 
applied to their apical surface and an apical wash was collected 0.5, 1, 1.5, 2, 2.5 
and 3 h after SPLUNC1 delivery. SPLUNC1 levels measured in apical wash 
samples by ELISA were significantly higher in SPLUNC1-treated as compared to 
PBS-treated cells (Figure 4.1). To determine whether this would also be the case in 
vivo, we dosed mice with SPLUNC1Δ19 i.t. and collected BAL at various time points 
post-administration. We show here that SPLUNC1 levels were more than 90X higher 
1 h after SPLUNC1 treatment as compared to PBS treatment taking into account the 
dose administered (Figure 4.2A). The SPLUNC1 levels remained above baseline for 
at least 24 h after SPLUNC1 administration. We supplement these data with 
Western blot results to illustrate that the increase in SPLUNC1 is not simply due to 
measuring the administered protein in the ELISA. First, we provide evidence that the 
exogenous recombinant SPLUNC1 administered runs at a smaller size than the 
endogenous protein (Figure 4.2B). We show this by comparing naïve wildtype 
mouse BAL which only contains endogenous SPLUNC1 with SPLUNC1-/- mouse 
BAL and recombinant protein. The endogenous wildtype SPLUNC1 runs at 35 kDa 
while the recombinant protein runs at 25 kDa. No protein was detected in the 
SPLUNC1-/- BAL. When we administered SPLUNC1Δ19 to mice, the endogenous 35 
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kDa SPLUNC1 protein band intensity increased (Figure 4.2C). These results show 
both in vitro in HBECs and in vivo in mice that the administration of SPLUNC1 
results in the release of SPLUNC1. 
SPLUNC1 Secretion is Specific to SPLUNC1 Administration 
To show SPLUNC1 secretion is specific to SPLUNC1 administration, we 
administered a 25 kDa protein pantothenate kinase (PanK), which was prepared in 
the laboratory using a similar method as SPLUNC1, and LPS. We show in Figure 
4.3 that only the administration of SPLUNC1 resulted in the abundant secretion of 
SPLUNC1. 
SPLUNC1 Concentration Increase is Not Sustained in Allergic Inflammation 
Thus far, we have shown that SPLUNC1 administration results in the 
secretion of SPLUNC1 in normal HBECs and naïve animals and that this effect is 
specific to the administration of SPLUNC1. We suggest in chapter 2 that SPLUNC1 
administration be evaluated for reducing AHR in allergic inflammation. We 
hypothesized that the release of endogenous SPLUNC1 contributes to the protective 
effect observed in Mch challenge and sought to evaluate the ability of mice to 
secrete SPLUNC1 in an allergic inflammatory state. We administered exogenous 
SPLUNC1Δ19 and SPLUNC1Δ44 to HDM-allergic wildtype mice and measured 
SPLUNC1 in the BAL at several time points after administration. We report that the 
administration of wildtype SPLUNC1Δ19 and mutant SPLUNC1Δ44 both result in 
increased SPLUNC1 in BAL but that the increase appears to be sustained for a 
shorter duration in HDM-allergic as compared to PBS-dosed mice (Figure 4.4A, 
4.4B). Although the administration of SPLUNC1 results in the increased 
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concentration of SPLUNC1 in the BAL, the duration for the increase is much longer 
in the PBS-treated than the HDM-allergic mice. Since SPLUNC1 has been shown to 
be reduced in the lungs during allergic inflammation, we speculate that the allergic 
inflammatory milieu may diminish the ability to sustain a SPLUNC1 concentration 
increase through suppression of transcription or reduction of intracellular SPLUNC1 
stores.  
Discussion 
We suggest in chapters 1 and 2 that SPLUNC1 administration or methods to 
increase endogenous SPLUNC1 be investigated for treatment of asthma and lung 
infection. We show here that administration of SPLUNC1 itself results in the release 
of endogenous SPLUNC1 and that this effect is specific to the administration of 
SPLUNC1. We also note that the increase in SPLUNC1, while sustained in naïve 
and PBS-treated mice, had a shorter duration of increase in our preliminary studies 
with allergic inflammation. Thus far, it is unclear whether this effect has therapeutic 
significance in terms of AHR as SPLUNC1Δ19 and SPLUNC1Δ44 had similar 
preliminary results for the release of endogenous SPLUNC1 while the two proteins 
had substantially differing results with regard to AHR (Figure 2.4 and 2.7A). More 
investigation is needed to confirm the preliminary findings and to determine what the 
results may mean with regard to AHR and infection. 
Future Directions 
Although we begin in this chapter to unravel the idea that SPLUNC1 
administration results in the release of endogenous SPLUNC1, many of the reported 
results are preliminary findings leaving more experiments left to complete. More 
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mice should be given SPLUNC1 i.t. and BAL collected at the 1, 12, 24, 48 and 72 h 
time points (Figure 4.2A). The goals are to increase the n numbers and to see if 
error may be reduced with more animals especially at the 1 h time point. 
Additionally, more mouse BAL should be tested by Western blot and the results 
normalized to obtain a quantitative evaluation of the increase in SPLUNC1 through 
Western blot. This method could exclude the exogenously administered 25 kDa 
SPLUNC1 which the ELISA technique is not able to separate out due to the antibody 
recognition of both endogenous and recombinant proteins. 
More mice also need to be given PanK and LPS in order to increase the n 
numbers to show that only SPLUNC1 administration results in the release of 
SPLUNC1 (Figure 4.3). Additionally, the drugs which have been published to 
increase the SPLUNC1 concentration in the lungs should be tested and BAL 
collected for evaluation of SPLUNC1 content. The goal is to compare the 
administration of SPLUNC1 with α1-antitrypsin, beta-2-agonists and glucocorticoids. 
We would like to investigate whether the amount of SPLUNC1 released differs 
between the various treatments currently shown to increase SPLUNC1. Future 
directions also include testing these drugs in HDM-allergic mice and the evaluation 
of AHR.  
In figure 4.4, we show that SPLUNC1’s ability to reduce AHR does not 
correlate with release of endogenous SPLUNC1. SPLUNC1Δ19 and SPLUNC1Δ44 
administration both result in similar release of SPLUNC1 into the BAL however, 
SPLUNC1Δ19 reduces AHR while SPLUNC1Δ44 does not. As SPLUNC1 release does 
not appear to correlate with AHR outcome, we would like to determine whether or 
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not SPLUNC1 release correlates with an ability to reduce bacterial burden in acute 
lung infection.  
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Figure 4.1. SPLUNC1 Increases SPLUNC1 Secretion by HBECs 
HBECs were cultured at air-liquid interface for 4-6 weeks and SPLUNC1 levels were 
measured in apical wash samples 1 h after the addition of apical PBS (white bars) or 
SPLUNC1 (black bars, 50 µg) by ELISA. n=5. P<0.05 between PBS and SPLUNC1 
groups by Wilcoxon matched-pairs signed rank test. 
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Figure 4.2. SPLUNC1 Administration Increases SPLUNC1 Secretion in Mouse 
BAL up to 48 Hours Post-administration 
A. C57BL/6 mice were dosed with SPLUNC1 (80 µg i.t.) or PBS ((-) Control). BAL 
was collected at the indicated time points and SPLUNC1 levels measured in the BAL 
supernatants by ELISA. Inset shows combined (-) Control PBS result from all time 
points. n=3-4 for all SPLUNC1 groups and n=11 for (-) Control. Mann-Whitney test. 
*P<0.05 **P<0.005  
B. BAL was collected from C57BL/6 (WT) and SPLUNC1-/- mice and SPLUNC1 was 
evaluated in BAL supernatants by Western blot. Rightmost lane shows recombinant 
wildtype SPLUNC1Δ19 alone. 
C. C57BL/6 and SPLUNC1-/- mice were dosed with SPLUNC1 (80 µg i.t.). BAL was 
collected 1 h later and SPLUNC1 was evaluated in BAL supernatants by Western 
blot. Rightmost lane shows recombinant wildtype SPLUNC1Δ19 alone. 
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Figure 4.3 SPLUNC1 Secretion in Mice is Specific to SPLUNC1 Administration 
C57BL/6 mice were dosed with SPLUNC1 (150 µg i.t.), LPS (5 µg or 50 µg i.t.), an 
unrelated 25 kDa protein pantothenate kinase (PanK, 150 ug i.t.) or PBS. BAL was 
collected one hour later and SPLUNC1 levels measured in the BAL supernatants by 
ELISA. n=2 for all groups except PanK n=1. 
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Figure 4.4 SPLUNC1 Secretion Remains High at least 24 h after SPLUNC1 
Administration in Controls but Decreases Rapidly in HDM-Allergic Mice. 
C57BL/6 mice were treated with HDM (25 μg i.n.) or PBS for 12 d. One day after the 
last HDM challenge, mice were dosed with  
A. Wildtype SPLUNC1Δ19 (150 μg i.t.) or 
B. SPLUNC1Δ44 (150 μg i.t.) 
and BAL was collected at the indicated time points. Open bars: PBS+ SPLUNC1; 
closed bars: HDM+ SPLUNC1. n=2-3 for all groups except PBS+SPLUNC1 Δ44 12 h 
and 24 h time points were not tested. Mann-Whitney test.  
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APPENDIX: P. aeruginosa Infection and PilY1 
Introduction 
As introduced in chapter 2, P. aeruginosa in a common opportunistic 
pathogen. This bacterium routinely affects patients with burns, cystic fibrosis, COPD, 
those who are immunocompromised, and is a primary Gram-negative infectious 
bacterium in patients with hospital-acquired pneumonia. Critical care infection rates 
have been reported as greater than 70% in ICU patients remaining at the hospital for 
longer than 7 days and P. aeruginosa is the leading multi-drug resistant (MDR) 
Gram-negative organism causing ventilator associated pneumonia (VAP) in ICU and 
burn patients (124-126). With increasing infection rates and incidence of MDR P. 
aeruginosa, we sought to investigate new potential prophylactic agents for this 
pathogen. 
As previously published by our group, P. aeruginosa binds to integrins via an 
RGD (arginine-glycine-aspartic acid) domain on the type IV pilus-associated PilY1 
protein (127). This binding is involved in P. aeruginosa attachment to human cells, 
and consequently PilY1 has a role in mediating infection. We sought to elucidate the 
mechanistic details of Pseudomonas infection via the type IV pilus and also 
investigate potential prophylactic therapies for bacterial pneumonia.  
Aims 
The aims of the project were: 1) Use x-ray crystallography to extend the 
previously determined three dimensional structure of P. aeruginosa PAK strain PilY1 
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to amino acids 532-1163 and 191-1163 which both include the critical pilus RGD 
motif (128). An alternative is to use PA14 strain PilY1 (amino acids 200-1170). 
Obtaining an extended crystal structure would facilitate a detailed understanding of 
how the RGD is presented for integrin binding to human cells. These data are 
expected to lead to the development of specific, directed prophylactic measures for 
preventing binding and subsequent infection by P. aeruginosa. 2) Administer PilY1 
to healthy and damaged lung epithelial cells in vitro in collaboration with the 
laboratory of Matthew Wolfgang. Artificial ventilation causes damage to lung 
epithelial cells and this study would help in the understanding of how pilus 
interaction with damaged tissue differs from healthy tissue. This aim involves 
observing PilY1 and integrin co-localization as well as wound healing. In order to 
visualize the protein, a biotin tag will be added to the protein’s C-terminus. 3) 
Administer cyclic RGD peptides in collaboration with the Wolfgang lab to lung 
epithelial cells in vitro followed by P. aeruginosa to evaluate binding and infection 
rate. The purpose is to occupy cell surface integrins with the cyclic RGD peptide, 
preventing P. aeruginosa from establishing an infection. 4) Administer cyclic RGD 
peptide in vivo to mouse lung using i.n. or i.t. delivery to a clinically relevant burn 
model in collaboration with the laboratory of Bruce Cairns (UNC School of Medicine). 
Mice are to receive 20% total body surface area (TBSA) burns to the dorsum which 
would produce first pro-inflammatory and then anti-inflammatory responses. The 
mice would be administered cyclic RGD peptide and infected with P. aeruginosa i.t. 
If the cyclic RGD peptide is successful at inhibiting bacterial pneumonia, the mice 
would be expected exhibit decreased colonization of bacteria in the lungs relative to 
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infected mice which did not receive cyclic RGD peptide treatment. Taken together, 
these investigations, which extend from atomic-level to animal studies, would help 
clarify the mechanism of Pseudomonas infection, elucidate how bacteria affect 
damaged vs. healthy cells, and potentially identify a new structure-based 
prophylactic approach for the prevention of nosocomial bacterial pneumonia with the 
potential to overcome current mechanisms of drug resistance. 
Preliminary Progress 
P. aeruginosa PilY1 PAK Strain Amino Acids 532-1163 and 191-1163 and PA14 
Strain Amino Acids 200-1170 Cloning 
PAK PilY1 532-1163 corresponding DNA was cloned into a ligation 
independent cloning vector with a 6X histidine (His6) tag. PAK PilY1 191-1163 DNA 
was cloned into ligation independent cloning vectors with His6 and maltose binding 
protein (MBP) tags. The PilY 191-1163 MBP vector was transformed into BL21-Gold 
and BL21-OrigamiTM cells and purification was performed using the BL21-Gold cells 
which resulted in the elution of the protein in the void volume. It is possible that the 
protein aggregated due to cysteines forming inappropriate disulfide bonds.  
PA14 200-1170 DNA was cloned into a ligation independent cloning vector 
with a His6 tag and transformed into BL21-AITM, BL21-Gold and BL21-OrigamiTM 2 
cells. An expression test revealed that BL21-Gold cells had slight but visible 
induction of protein in the soluble fraction after one and two hours of induction. The 
BL21-AITM soluble fraction did not have visible protein. Sequence confirmation 
revealed a C477G and a silent mutation at amino acid 645.  
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PAK PilY1 532-1163 Cloning into Avidity Vector for Biotinylation  
PAK PilY1 532-1163 DNA was successfully cloned into the pAC6 AviTagTM 
vector and the sequence confirmed.  
Administration of Cyclic RGD Peptides to Mice 
An IACUC amendment was submitted and approved for the administration of 
cyclic RGD peptides to mice. A 20% TBSA burn is to be given to the dorsum of mice 
followed by resuscitation and analgesia. One, three, seven and fourteen days after 
burn procedure, between 5 x 104 and 5 x 109 of RGD molecules are to be delivered 
to the mice followed by between 1 x 103 and 1 x 106 CFU of P. aeruginosa. After 
one, two and three days the mice will be euthanized and blood, lung and BAL 
collected from each mouse for evaluation of bacterial recovery.  
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